Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns

Stock Track05-08

Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.

The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.

The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170799787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170799787","market":"us","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns","media":"Stock Track","content":"<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Plummets 5.01% Intraday as H.C. Wainwright Cuts Target Price Amid Clinical Data Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 01:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.</p><p>The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.</p><p>The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1170799787","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170799787","pubTimestamp":1778174117,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|Summit Therapeutics盘中暴跌5.01%因H.C.由于临床数据担忧，温赖特下调目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC's stock plummeted 5.01% during intraday trading on Thursday, extending recent weakness in the biotechnology sector.The decline follows H.C. Wainwright's decision to cut its target price on the company from $30 to $23, compounding ongoing negative sentiment from the HARMONi-3 study's interim progression-free survival analysis in squamous non-small cell lung cancer, which failed to reach statistical significance. Multiple institutions have since lowered their target prices, creating a negative resonance effect in the market.The company had previously disclosed that the HARMONi-3 interim data failed to meet success criteria, triggering a significant single-day decline in late April. While the stock had briefly rebounded after some analysts maintained positive ratings, H.C. Wainwright's recent downgrade has again weighed on market confidence. Investors are now looking ahead to the final HARMONi-3 PFS results expected in the second half of the year and the upcoming HARMONi-6 overall survival data presentation at ASCO.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170799787","isCrawlerRequest":true}